Navigation Links
Frost & Sullivan Recognizes Singulex for Erenna(R) Immunoassay System
Date:6/15/2009

Enabling High Resolution Monitoring of Drug Efficacy and Safety

MOUNTAIN VIEW, Calif., June 15 /PRNewswire/ -- Based on its recent analysis in the area of immunoassay technologies for biomarker measurement, Frost & Sullivan recognizes Singulex, Inc. with the 2009 North American Frost & Sullivan Award for Technology Innovation for pioneering the Erenna Immunoassay System. This system incorporates single molecule counting (SMC) technology into next-generation immunoassays, significantly impacting early disease management and patient monitoring.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

Pharmaceutical partners are using this system to implement advanced biomarker monitoring programs that address drug safety and efficacy. The Erenna system offers the unique advantage of high-resolution monitoring of key disease biomarkers due to its unrivaled sensitivity and precision, which can enable early decision making and reduce the over-all cost of drug development. Through collaborative efforts, Singulex is helping to deliver better medicine with an unsurpassed safety/efficacy profile in a cost-effective manner.

The Erenna Immunoassay System simplifies clinical trial management by bridging the gap between preclinical and clinical assessment of protein biomarkers for disease. The system offers full flexibility, providing users a broad assay menu and custom assay development services to discover the effect of therapeutic intervention on biological pathways of interest.

"In deploying the high sensitivity platform, the company has developed a broad menu of novel ultrasensitive immunoassays that offer a better understanding of early disease processes and the impact of therapeutic interventions by measuring biomarker levels in blood samples," observes Philippe Goix, CEO. "Singulex is also building on its diagnostic business by offering our proprietary Molecular Cardiac Troponin-I (cTnI) testing services in our CLIA laboratory for early detection and monitoring of cardiovascular disease risk."

The Erenna Immunoassay System is a simple, easy-to-use bench-top analytical instrument with ready-made reagents that provides high-resolution results directly from biological specimens such as serum or plasma. The system includes data management software and can be integrated into an existing clinical laboratory workflow. The system can also be integrated with automated robotic handling units to provide high throughput capabilities for biomarker quantification and validation.

"The technology behind the Erenna system comprises two important stages: a modified microparticle (MP)-based sandwich immunoassay followed by a single molecule counting technology," explains Frost & Sullivan Healthcare Industry Analyst Pramodh Ishwarakrishnan. "The system combines a 384-well plate format for sample analysis, capillary flow, laser-induced fluorescence, and a highly sensitive detection optics module."

Increased sensitivity and precision are essential for robust measurement of disease biomarkers, and the Erenna system enables high resolution monitoring by accurately quantifying minute changes in biomarker concentration in patient specimens over time. The Erenna system measures each fluorescent-labeled detection antibody as a unique digital event separate from the background fluorescent signal, unlike conventional analog systems that count the total light together with background. Thus, the system offers enhanced specificity, sensitivity, and precision by 1 to 2 logs over existing plate-based methods.

Each year, Frost & Sullivan presents this award to the company (or individual) that has carried out new research that has resulted in innovation(s) that have or are expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. This award recognizes the quality and depth of a company's research and development program as well as the vision and risk-taking that enabled it to undertake such an endeavor.

Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Singulex, Inc.

Singulex, Inc. manages risks by answering critical health questions about disease and therapeutic intervention utilizing cutting edge immunodiagnostic products. Singulex has pioneered technology that can quantitatively detect single molecules such as proteins and metabolites in complex biological samples. The technology embedded in the Erenna System extends the dynamic range of any immunoassay by orders of magnitude, allowing drug developers to use biomarkers to measure drug efficacy, safety, and disease progression. The company also focuses on advancing industry-leading sample analysis and assay development services. Singulex has assembled a team of scientists who are experts in the field of immunoassay development to ensure that all products are manufactured to the highest standards.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

    Contact:
    Jake Wengroff
    210.247.3806
    jake.wengroff@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Supernanny Jo Frost Joins the Partnership for a Drug-Free America in Supporting Time To Talk(TM)
2. Masimo Corporation Receives a Frost & Sullivan 2007 Industry Best Practices Award for Pulse Oximetry Leadership
3. Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award
4. Novadaqs SPY Imaging System named Product of the Year by Frost and Sullivan
5. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
6. Kelloggs Frosted Flakes Gold(TM) Helps Moms Get the Gold
7. MedApps Receives Prestigious Frost & Sullivan Award
8. Nancy Frost Joins Lawson-Hawks as Employee Benefits Vice President
9. Accurays CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan
10. Help Your Kids Earn an A for Attentiveness with a Bowl of Frosted Mini- Wheats(R) Cereal for Breakfast
11. Therapy Could Save Limbs After Frostbite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... Dr. ... Board of Dermatology and fellowship trained Mohs and cosmetic surgeon. After extensive dermatology ... Dr. Li completed his internship in internal medicine at the Emory University and ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... now offering treatments for patients with sleep apnea and TMJ disorders. These conditions ... and physical health. Dr. Rassouli provides personalized care to reduce the risk of ...
(Date:1/19/2017)... ... January 19, 2017 , ... Rountree ... planning services to communities throughout eastern Georgia, is embarking on a charity effort ... Heart disease kills more Americans every year than anything else, yet risk factors ...
(Date:1/19/2017)... ... January 19, 2017 , ... Creative messages ... Real Impact contest from Impact Teen Drivers and California Casualty. Entries from students ... , Educational grants totaling $15,000 will be awarded for the best peer-to-peer messages ...
(Date:1/19/2017)... ... , ... The 21st Century Cures Act’s Impact on Medical Devices:, What You ... 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          , What do ... this year? , The passage of the act means devicemakers will be scrambling to ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
(Date:1/19/2017)... 19, 2017 Shire plc (LSE: ... U.S. Food and Drug Administration (FDA) has acknowledged receipt ... Application (NDA) for SHP465, a long-acting, triple-bead, mixed amphetamine ... once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is ... 20, 2017, the designated Prescription Drug User Fee Act ...
(Date:1/19/2017)... The global  pacemaker market  is expected to reach USD ... Inc. The heightening prevalence of cardiac conditions coupled with the availability of medical ... addition, technological enhancements in these devices are supporting the expansion of this vertical. ... ... Grand View Research Logo ...
Breaking Medicine Technology: